



**Contacts:** Frank Cano, Ph.D. (Investors)  
Vaxin Chairman and CEO  
650 949-1750  
cano@vaxin.com

Debra Bannister (Media)  
530 676-8001

debban@pacbell.net

## **International Vaccine Expert Dr. Alf Lindberg Joins Vaxin Board of Directors**

-Vaxin Preparing for Flu Vaccine Clinical Trials with Experienced Management Team in Place-

**Birmingham, AL – July 8, 2004** – Vaxin Inc. announced today the appointment of Alf Lindberg, M.D., Ph.D., former Executive Vice President of Research and Development at Aventis Pasteur, to its Board of Directors. With the addition of Dr. Lindberg, and several recently appointed new members of the management team, the company is preparing for additional Phase I/II clinical trials for its nasal delivery influenza vaccine. By applying its proprietary technology, which uses non-invasive means to elicit an immune response, Vaxin is developing new vaccines for influenza, anthrax and other diseases.

“Vaxin is fortunate to have the scientific leadership of Dr. Lindberg as Chairman of our Scientific Advisory Board, and we are delighted that he has accepted an appointment to the Board of Directors,” said Frank Cano, Ph.D., Chairman and Chief Executive Officer. “Dr. Lindberg’s vast experience in science, medicine and pharmaceutical research and development will contribute greatly to Vaxin as we move towards commercial application of our technology. In preparation for advancing our lead programs – a flu vaccine into Phase I/II clinical trials; a tetanus vaccine into Phase I; and an anthrax vaccine into Phase I – we’ve also recently added significant depth of experience to our management team.”

Dr. Lindberg’s distinguished career encompasses academic appointments at the prestigious Karolinska Institute, Stanford University School of Medicine and Walter Reed Army Institute of Research. In addition to his executive positions at Aventis Pasteur and Pasteur Merieux Connaught in France, he was Chief Scientific Officer and Vice President at Wyeth-Lederle Vaccines & Pediatrics in the US. Dr. Lindberg has also served as a consultant to a number of biotechnology and pharmaceutical companies. As secretary of the Medical Nobel Assembly at the Karolinska Institute, Dr. Lindberg was involved in selecting the Nobel Laureates in Medicine. At the same time, Dr. Lindberg was a member of the Board of Directors of the Nobel Foundation. He is a board member of several private and public biopharmaceutical companies and, for Aventis, serves as both a member of its Scientific Advisory Board and as an Advisor to the Head of Research and Development.

“It is with great pleasure that I can increase my commitment to Vaxin as a member of its Board of Directors,” Dr. Lindberg commented. “I believe that the combination of Vaxin’s novel technology, strong intellectual property and dedicated people will enable the company’s future success.”

Recently joining Dr. Cano on the Vaxin management team, which includes President and Chief Operating Officer Kent Van Kampen, D.V.M., Ph.D., and Vaxin's scientific founder, Vice President and Chief Technical Officer, De-chu Tang, Ph.D., are:

- Victor A. Jegede, Ph.D., Vice President of Quality
- Dennis W. Trent, Ph.D., Vice President of Scientific and Regulatory Affairs
- David Novack, Vice President, Business Development
- Deborah Schueren, Chief Financial Officer

Vaxin Inc. is an emerging biotechnology company developing vaccines and other biological products that address large markets, utilizing its proprietary technology for non-invasive delivery to the skin and nasal passages. The company's products use non-replicating recombinant adenovirus or inactivated bacterial vectors to deliver vaccine antigens to the skin or nasal mucosa where they stimulate a protective immune response. This method has been tested in proof-of-principle animal studies as well as a Phase I human clinical trial. The Vaxin vaccine products are expected to be safe and should elicit a potent immune response. In addition, they can be produced in culture, which provides higher yields at lower cost than traditional vaccine manufacturing. Initial product development is targeted towards improved influenza and combination tetanus/diphtheria vaccines as well as a novel anthrax vaccine. The company has raised more than \$15 million in venture capital and government grants.